These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
133 related items for PubMed ID: 12324983
1. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Morris AD. Diabetes Metab Res Rev; 2002; 18 Suppl 3():S32-5. PubMed ID: 12324983 [Abstract] [Full Text] [Related]
2. [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. Marissal JP, Sailly JC, Crainich D, Lebrun T. Rev Epidemiol Sante Publique; 2005 Sep; 53 Spec No 1():1S67-78. PubMed ID: 16327742 [Abstract] [Full Text] [Related]
4. [Patient classification and analysis of risk profiles for type 2 diabetics as the main focus point in practice. Results of the TEMPO study]. Lippmann-Grob B, Bierwirth RA, Kron P, Leinhos B, Funke K, Huptas M, Grüneberg M, Weich KW, Münscher C, Potthoff F. Dtsch Med Wochenschr; 2004 Jan 16; 129(3):75-81. PubMed ID: 14724780 [Abstract] [Full Text] [Related]
5. Economic costs of diabetes in the U.S. In 2007. American Diabetes Association. Diabetes Care; 2008 Mar 16; 31(3):596-615. PubMed ID: 18308683 [Abstract] [Full Text] [Related]
6. Improving oral pharmacologic treatment and management of type 2 diabetes. Dailey GE. Manag Care; 2004 Feb 16; 13(2):41-7. PubMed ID: 15004930 [Abstract] [Full Text] [Related]
7. A systems approach to diabetes care. Mazze RS. Diabetes Care; 1994 Jun 16; 17 Suppl 1():5-11. PubMed ID: 8088224 [Abstract] [Full Text] [Related]
8. The cost of medical care for patients with diabetes, hypertension and both conditions: does alcohol use play a role? French MT, Mundt MP, Fleming M, Zavala SK. J Intern Med; 2005 Jul 16; 258(1):45-54. PubMed ID: 15953132 [Abstract] [Full Text] [Related]
9. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KM, Nwachuku C, O'Connor PJ, Zhang P, ACCORD Study Group. Am J Cardiol; 2007 Jun 18; 99(12A):90i-102i. PubMed ID: 17599429 [Abstract] [Full Text] [Related]
10. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Davis WA, Knuiman MW, Hendrie D, Davis TM. Intern Med J; 2006 Mar 18; 36(3):155-61. PubMed ID: 16503950 [Abstract] [Full Text] [Related]
11. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study. James P, Tan HH, MacAlpine R, Brennan G, Emslie-Smith A, Morris AD. Diabet Med; 2004 Oct 18; 21(10):1108-12. PubMed ID: 15384958 [Abstract] [Full Text] [Related]
14. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study]. von Ferber L, Köster I, Hauner H. Med Klin (Munich); 2006 May 15; 101(5):384-93. PubMed ID: 16685485 [Abstract] [Full Text] [Related]
18. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Larrañaga I, Arteagoitia JM, Rodriguez JL, Gonzalez F, Esnaola S, Piniés JA, Sentinel Practice Network of the Basque Country. Diabet Med; 2005 Aug 15; 22(8):1047-53. PubMed ID: 16026371 [Abstract] [Full Text] [Related]
19. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Killilea T. Am J Manag Care; 2002 Oct 15; 8(16 Suppl):S441-9. PubMed ID: 12408407 [Abstract] [Full Text] [Related]
20. The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetes. McAlpine RR, Morris AD, Emslie-Smith A, James P, Evans JM. Diabet Med; 2005 Mar 15; 22(3):348-52. PubMed ID: 15717888 [Abstract] [Full Text] [Related] Page: [Next] [New Search]